# Mendus

Source: https://onco.cc/companies/mendus/  
OnCo record `mendus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mendus makes an off-the-shelf cell-based cancer vaccine, given as a skin injection after standard treatment, to stop leukaemia and ovarian cancer from coming back.

## Summary

Mendus AB (Nasdaq Stockholm: IMMU) is headquartered in Stockholm with research and development in Leiden. Lead programme vididencel (DCP-001) is an allogeneic active immunotherapy derived from a proprietary leukaemia cell line; given intradermally it triggers local immune activation and tumour-directed immune responses against residual disease. It is being developed as maintenance therapy in acute myeloid leukaemia (ADVANCE II and CADENCE), in high-risk ovarian cancer (ALISON), where in June 2026 the company reported long-term progression-free survival with broad immune activation and five participants progression-free at long-term follow-up, and in chronic myeloid leukaemia for treatment-free remission (VITAL-CML, first stage fully enrolled in 2026). A second asset, ilixadencel, is an intratumoural allogeneic dendritic cell product. No equity round could be sourced from fetched pages; in June 2026 the company repurchased outstanding warrants from Fenja for about SEK 3.7 million.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Stockholm
- Type: biotech
- Website: https://www.mendus.com
- Ticker: IMMU.ST

## Notes

- Founding year and rights issues not sourced from fetched pages.

## Sources

- Official website: https://www.mendus.com
- Press releases: https://www.mendus.com/investors/press-releases/
- Pipeline and technology: https://www.mendus.com/what-we-do/

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)

---
JSON: https://onco.cc/api/v1/entities/mendus.json